Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

To be considered for the main part of the study (Core Phase), you would generally need to have a diagnosis of multiple sclerosis. Your MS should also have shown some activity recently, such as having at least one flare-up in the past year, or two in the last two years, or signs of new activity on an MRI scan within the last six months. Your MS symptoms should also be within a certain range of mild to moderate.

There are also reasons why someone might not be able to join. For example, if you have a type of MS called 'progressive MS,' have another active long-term immune system condition, certain severe heart problems, or severe kidney problems, you wouldn't be eligible. Also, if you have a specific condition called ADEM (Acute Disseminated Encephalomyelitis), you would not be able to take part.

For the second part of the study (Extension Phase), patients who successfully completed the Core Phase can continue. New younger patients might also be able to join the Extension Phase directly if they meet specific criteria for their age group and MS diagnosis, as approved by local health authorities.

If you decide to take part in this study, it's a long-term commitment. The first part, called the Core Phase, lasts for two years. During this time, you would regularly visit the study clinic for check-ups, assessments, and to receive your study medication, which would be either fingolimod or interferon beta-1a. You wouldn't know which one you're getting, and neither would your doctors, to ensure fair results. You'll likely have regular MRI scans and other tests to monitor your MS and your general health.

After the two-year Core Phase, if you meet the requirements, you can then join the Extension Phase, which can last for up to five more years. In this longer phase, everyone in the study receives fingolimod. You would continue to have regular clinic visits, assessments, and tests to see how you're responding to the treatment over the long term. The total duration for someone who completes both phases could be up to seven years. Throughout the study, your health will be closely monitored, and any side effects will be carefully recorded.